JP2009542638A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009542638A5 JP2009542638A5 JP2009518044A JP2009518044A JP2009542638A5 JP 2009542638 A5 JP2009542638 A5 JP 2009542638A5 JP 2009518044 A JP2009518044 A JP 2009518044A JP 2009518044 A JP2009518044 A JP 2009518044A JP 2009542638 A5 JP2009542638 A5 JP 2009542638A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- alkyl
- fluoro
- imidazol
- pyrimidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 56
- -1 3-tetrahydropyranyl Chemical group 0.000 claims 35
- 229910052757 nitrogen Inorganic materials 0.000 claims 28
- 125000005843 halogen group Chemical group 0.000 claims 27
- 150000001875 compounds Chemical class 0.000 claims 26
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 24
- 125000000623 heterocyclic group Chemical group 0.000 claims 22
- 229910052799 carbon Inorganic materials 0.000 claims 21
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 17
- 239000001257 hydrogen Substances 0.000 claims 13
- 229910052739 hydrogen Inorganic materials 0.000 claims 13
- 125000003545 alkoxy group Chemical group 0.000 claims 12
- 208000010877 cognitive disease Diseases 0.000 claims 10
- 206010012289 Dementia Diseases 0.000 claims 8
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 8
- 206010026749 Mania Diseases 0.000 claims 8
- 208000024827 Alzheimer disease Diseases 0.000 claims 6
- 208000028698 Cognitive impairment Diseases 0.000 claims 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 6
- 230000011164 ossification Effects 0.000 claims 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 6
- 125000004487 4-tetrahydropyranyl group Chemical group [H]C1([H])OC([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 5
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 5
- 125000002837 carbocyclic group Chemical group 0.000 claims 5
- 150000002431 hydrogen Chemical class 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 230000002265 prevention Effects 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims 4
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 4
- 208000020925 Bipolar disease Diseases 0.000 claims 4
- 208000026072 Motor neurone disease Diseases 0.000 claims 4
- 208000018737 Parkinson disease Diseases 0.000 claims 4
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 4
- 230000007000 age related cognitive decline Effects 0.000 claims 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 125000002140 imidazol-4-yl group Chemical group [H]N1C([H])=NC([*])=C1[H] 0.000 claims 4
- 208000027061 mild cognitive impairment Diseases 0.000 claims 4
- 230000036651 mood Effects 0.000 claims 4
- 208000005264 motor neuron disease Diseases 0.000 claims 4
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 4
- 201000000980 schizophrenia Diseases 0.000 claims 4
- 230000009529 traumatic brain injury Effects 0.000 claims 4
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 4
- 206010017076 Fracture Diseases 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims 3
- 125000002861 (C1-C4) alkanoyl group Chemical group 0.000 claims 2
- 125000004845 (C1-C6) alkylsulfonylamino group Chemical group 0.000 claims 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 2
- 208000017194 Affective disease Diseases 0.000 claims 2
- 201000004384 Alopecia Diseases 0.000 claims 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 2
- 208000010392 Bone Fractures Diseases 0.000 claims 2
- 208000011990 Corticobasal Degeneration Diseases 0.000 claims 2
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 2
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 2
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims 2
- 201000010374 Down Syndrome Diseases 0.000 claims 2
- 208000027534 Emotional disease Diseases 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 208000009829 Lewy Body Disease Diseases 0.000 claims 2
- 201000002832 Lewy body dementia Diseases 0.000 claims 2
- 208000019022 Mood disease Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000014060 Niemann-Pick disease Diseases 0.000 claims 2
- 206010034010 Parkinsonism Diseases 0.000 claims 2
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 2
- 208000024571 Pick disease Diseases 0.000 claims 2
- 208000024777 Prion disease Diseases 0.000 claims 2
- 206010044688 Trisomy 21 Diseases 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 201000004810 Vascular dementia Diseases 0.000 claims 2
- 125000005236 alkanoylamino group Chemical group 0.000 claims 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 2
- 231100000360 alopecia Toxicity 0.000 claims 2
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 2
- 210000000988 bone and bone Anatomy 0.000 claims 2
- 230000037182 bone density Effects 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 210000004720 cerebrum Anatomy 0.000 claims 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 208000017004 dementia pugilistica Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000006125 ethylsulfonyl group Chemical group 0.000 claims 2
- 239000012458 free base Substances 0.000 claims 2
- 230000035876 healing Effects 0.000 claims 2
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 230000003902 lesion Effects 0.000 claims 2
- 238000012423 maintenance Methods 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 206010027175 memory impairment Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 210000002682 neurofibrillary tangle Anatomy 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical compound NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 claims 2
- 230000001737 promoting effect Effects 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 230000000698 schizophrenic effect Effects 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 230000006641 stabilisation Effects 0.000 claims 2
- 238000011105 stabilization Methods 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 125000004434 sulfur atom Chemical group 0.000 claims 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- VMGUWFGUMZRWDD-UHFFFAOYSA-N (2,6-dimethylpiperidin-1-yl)-[5-[[5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]pyridin-2-yl]methanone Chemical compound CC1CCCC(C)N1C(=O)C(N=C1)=CC=C1NC1=NC=C(F)C(C=2N(C(C)=NC=2)C2CCOCC2)=N1 VMGUWFGUMZRWDD-UHFFFAOYSA-N 0.000 claims 1
- WWGYXDWUEUVJCI-UHFFFAOYSA-N (3,3-difluoropyrrolidin-1-yl)-[5-[[5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]pyridin-2-yl]methanone Chemical compound C1COCCC1N1C(C)=NC=C1C(C(=CN=1)F)=NC=1NC(C=N1)=CC=C1C(=O)N1CCC(F)(F)C1 WWGYXDWUEUVJCI-UHFFFAOYSA-N 0.000 claims 1
- HKDAFXBCUWUUQP-UHFFFAOYSA-N (3,5-dimethylpiperidin-1-yl)-[5-[[5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]pyridin-2-yl]methanone Chemical compound C1C(C)CC(C)CN1C(=O)C(N=C1)=CC=C1NC1=NC=C(F)C(C=2N(C(C)=NC=2)C2CCOCC2)=N1 HKDAFXBCUWUUQP-UHFFFAOYSA-N 0.000 claims 1
- WDRSDPKRIOMBFL-UHFFFAOYSA-N (4,4-difluoropiperidin-1-yl)-[5-[[5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]pyridin-2-yl]methanone Chemical compound C1COCCC1N1C(C)=NC=C1C(C(=CN=1)F)=NC=1NC(C=N1)=CC=C1C(=O)N1CCC(F)(F)CC1 WDRSDPKRIOMBFL-UHFFFAOYSA-N 0.000 claims 1
- PIABFBSAORAFPU-UHFFFAOYSA-N (4-benzylpiperazin-1-yl)-[5-[[5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]pyridin-2-yl]methanone Chemical compound C1COCCC1N1C(C)=NC=C1C(C(=CN=1)F)=NC=1NC(C=N1)=CC=C1C(=O)N(CC1)CCN1CC1=CC=CC=C1 PIABFBSAORAFPU-UHFFFAOYSA-N 0.000 claims 1
- FLFRWPXYPISNIH-UHFFFAOYSA-N (4-butan-2-ylpiperazin-1-yl)-[5-[[5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]pyridin-2-yl]methanone Chemical compound C1CN(C(C)CC)CCN1C(=O)C(N=C1)=CC=C1NC1=NC=C(F)C(C=2N(C(C)=NC=2)C2CCOCC2)=N1 FLFRWPXYPISNIH-UHFFFAOYSA-N 0.000 claims 1
- GMQLLYIFZSEJPL-UHFFFAOYSA-N (4-butylpiperazin-1-yl)-[5-[[5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]pyridin-2-yl]methanone Chemical compound C1CN(CCCC)CCN1C(=O)C(N=C1)=CC=C1NC1=NC=C(F)C(C=2N(C(C)=NC=2)C2CCOCC2)=N1 GMQLLYIFZSEJPL-UHFFFAOYSA-N 0.000 claims 1
- OYCCDNYVHVFKKN-UHFFFAOYSA-N (4-ethylpiperazin-1-yl)-[5-[[5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]pyridin-2-yl]methanone Chemical compound C1CN(CC)CCN1C(=O)C(N=C1)=CC=C1NC1=NC=C(F)C(C=2N(C(C)=NC=2)C2CCOCC2)=N1 OYCCDNYVHVFKKN-UHFFFAOYSA-N 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- KWFFACXRLMOJGA-UHFFFAOYSA-N 5-[[5-fluoro-4-[2-methyl-3-(oxan-4-yl)-2,4-dihydroimidazol-4-yl]pyrimidin-2-yl]amino]-n-(2,2,2-trifluoroethyl)pyridine-2-sulfonamide Chemical compound CC1N=CC(C=2C(=CN=C(NC=3C=NC(=CC=3)S(=O)(=O)NCC(F)(F)F)N=2)F)N1C1CCOCC1 KWFFACXRLMOJGA-UHFFFAOYSA-N 0.000 claims 1
- LQEOPALZMNEMPG-UHFFFAOYSA-N 5-[[5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]-n,n-di(propan-2-yl)pyridine-2-carboxamide Chemical compound C1=NC(C(=O)N(C(C)C)C(C)C)=CC=C1NC1=NC=C(F)C(C=2N(C(C)=NC=2)C2CCOCC2)=N1 LQEOPALZMNEMPG-UHFFFAOYSA-N 0.000 claims 1
- SDSHRJYDKCXWJQ-UHFFFAOYSA-N 5-[[5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]-n-methyl-n-propan-2-ylpyridine-2-carboxamide Chemical compound C1=NC(C(=O)N(C)C(C)C)=CC=C1NC1=NC=C(F)C(C=2N(C(C)=NC=2)C2CCOCC2)=N1 SDSHRJYDKCXWJQ-UHFFFAOYSA-N 0.000 claims 1
- AFCZSQCTHGPWSN-UHFFFAOYSA-N 5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]-n-(5-methylsulfonylpyridin-2-yl)pyrimidin-2-amine;hydrochloride Chemical compound Cl.C1COCCC1N1C(C)=NC=C1C(C(=CN=1)F)=NC=1NC1=CC=C(S(C)(=O)=O)C=N1 AFCZSQCTHGPWSN-UHFFFAOYSA-N 0.000 claims 1
- NBKWSGUZFJHXCL-UHFFFAOYSA-N 5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]-n-(6-methylsulfonylpyridin-3-yl)pyrimidin-2-amine Chemical compound C1COCCC1N1C(C)=NC=C1C(C(=CN=1)F)=NC=1NC1=CC=C(S(C)(=O)=O)N=C1 NBKWSGUZFJHXCL-UHFFFAOYSA-N 0.000 claims 1
- GEQGNVINFPSPBG-UHFFFAOYSA-N 5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]-n-[6-(4-methylpiperazin-1-yl)sulfonylpyridin-3-yl]pyrimidin-2-amine Chemical compound C1CN(C)CCN1S(=O)(=O)C(N=C1)=CC=C1NC1=NC=C(F)C(C=2N(C(C)=NC=2)C2CCOCC2)=N1 GEQGNVINFPSPBG-UHFFFAOYSA-N 0.000 claims 1
- QIZMDSPMHSHDEB-UHFFFAOYSA-N 5-fluoro-n-(2-methoxypyrimidin-5-yl)-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-amine Chemical compound C1=NC(OC)=NC=C1NC1=NC=C(F)C(C=2N(C(C)=NC=2)C2CCOCC2)=N1 QIZMDSPMHSHDEB-UHFFFAOYSA-N 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 claims 1
- MIIHRHZPVFFLNV-UHFFFAOYSA-N [3-chloro-5-[[4-(2,3-dimethylimidazol-4-yl)-5-fluoropyrimidin-2-yl]amino]pyridin-2-yl]-(4-methylpiperazin-1-yl)methanone Chemical compound C1CN(C)CCN1C(=O)C(C(=C1)Cl)=NC=C1NC1=NC=C(F)C(C=2N(C(C)=NC=2)C)=N1 MIIHRHZPVFFLNV-UHFFFAOYSA-N 0.000 claims 1
- WXPPJJJNBYDKLN-UHFFFAOYSA-N [3-chloro-5-[[4-(2,3-dimethylimidazol-4-yl)-5-fluoropyrimidin-2-yl]amino]pyridin-2-yl]-piperidin-1-ylmethanone;hydrochloride Chemical compound Cl.CN1C(C)=NC=C1C1=NC(NC=2C=C(Cl)C(C(=O)N3CCCCC3)=NC=2)=NC=C1F WXPPJJJNBYDKLN-UHFFFAOYSA-N 0.000 claims 1
- HAFDEHIYHASOTC-UHFFFAOYSA-N [3-chloro-5-[[5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]pyridin-2-yl]-piperidin-1-ylmethanone;hydrochloride Chemical compound Cl.C1COCCC1N1C(C)=NC=C1C(C(=CN=1)F)=NC=1NC(C=C1Cl)=CN=C1C(=O)N1CCCCC1 HAFDEHIYHASOTC-UHFFFAOYSA-N 0.000 claims 1
- SKYXACSXHYZRJQ-UHFFFAOYSA-N [3-chloro-5-[[5-fluoro-4-[3-(oxan-4-yl)-2-(trifluoromethyl)imidazol-4-yl]pyrimidin-2-yl]amino]pyridin-2-yl]-(4-methylpiperazin-1-yl)methanone Chemical compound C1CN(C)CCN1C(=O)C(C(=C1)Cl)=NC=C1NC1=NC=C(F)C(C=2N(C(=NC=2)C(F)(F)F)C2CCOCC2)=N1 SKYXACSXHYZRJQ-UHFFFAOYSA-N 0.000 claims 1
- IMVUQMPEFGNUQU-UHFFFAOYSA-N [3-chloro-5-[[5-fluoro-4-[3-methyl-2-(trifluoromethyl)imidazol-4-yl]pyrimidin-2-yl]amino]pyridin-2-yl]-(4-methylpiperazin-1-yl)methanone Chemical compound C1CN(C)CCN1C(=O)C(C(=C1)Cl)=NC=C1NC1=NC=C(F)C(C=2N(C(=NC=2)C(F)(F)F)C)=N1 IMVUQMPEFGNUQU-UHFFFAOYSA-N 0.000 claims 1
- QTBWYPYVFWMGBX-UHFFFAOYSA-N [5-[[4-(2,3-dimethylimidazol-4-yl)-5-fluoropyrimidin-2-yl]amino]pyridin-2-yl]-(4-methylpiperazin-1-yl)methanone Chemical class C1CN(C)CCN1C(=O)C(N=C1)=CC=C1NC1=NC=C(F)C(C=2N(C(C)=NC=2)C)=N1 QTBWYPYVFWMGBX-UHFFFAOYSA-N 0.000 claims 1
- GLUHCPHQUQQXHV-UHFFFAOYSA-N [5-[[5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]pyridin-2-yl]-(3-methylpiperidin-1-yl)methanone Chemical compound C1C(C)CCCN1C(=O)C(N=C1)=CC=C1NC1=NC=C(F)C(C=2N(C(C)=NC=2)C2CCOCC2)=N1 GLUHCPHQUQQXHV-UHFFFAOYSA-N 0.000 claims 1
- HBZKNQHUWOKHRE-UHFFFAOYSA-N [5-[[5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]pyridin-2-yl]-(4-fluoropiperidin-1-yl)methanone Chemical compound C1COCCC1N1C(C)=NC=C1C(C(=CN=1)F)=NC=1NC(C=N1)=CC=C1C(=O)N1CCC(F)CC1 HBZKNQHUWOKHRE-UHFFFAOYSA-N 0.000 claims 1
- AQBKDIKKXJXICU-UHFFFAOYSA-N [5-[[5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]pyridin-2-yl]-(4-methoxypiperidin-1-yl)methanone Chemical compound C1CC(OC)CCN1C(=O)C(N=C1)=CC=C1NC1=NC=C(F)C(C=2N(C(C)=NC=2)C2CCOCC2)=N1 AQBKDIKKXJXICU-UHFFFAOYSA-N 0.000 claims 1
- OASYMNQFJRRPSA-UHFFFAOYSA-N [5-[[5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]pyridin-2-yl]-(4-methylpiperazin-1-yl)methanone Chemical compound C1CN(C)CCN1C(=O)C(N=C1)=CC=C1NC1=NC=C(F)C(C=2N(C(C)=NC=2)C2CCOCC2)=N1 OASYMNQFJRRPSA-UHFFFAOYSA-N 0.000 claims 1
- LPVSGOGWVBRZQH-UHFFFAOYSA-N [5-[[5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]pyridin-2-yl]-(4-methylpiperidin-1-yl)methanone Chemical compound C1CC(C)CCN1C(=O)C(N=C1)=CC=C1NC1=NC=C(F)C(C=2N(C(C)=NC=2)C2CCOCC2)=N1 LPVSGOGWVBRZQH-UHFFFAOYSA-N 0.000 claims 1
- BGXZVMCGKJNOLZ-UHFFFAOYSA-N [5-[[5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]pyridin-2-yl]-(4-propan-2-ylpiperazin-1-yl)methanone Chemical compound C1CN(C(C)C)CCN1C(=O)C(N=C1)=CC=C1NC1=NC=C(F)C(C=2N(C(C)=NC=2)C2CCOCC2)=N1 BGXZVMCGKJNOLZ-UHFFFAOYSA-N 0.000 claims 1
- UVUACLWYQOMFIS-UHFFFAOYSA-N [5-[[5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]pyridin-2-yl]-(4-propylpiperazin-1-yl)methanone Chemical compound C1CN(CCC)CCN1C(=O)C(N=C1)=CC=C1NC1=NC=C(F)C(C=2N(C(C)=NC=2)C2CCOCC2)=N1 UVUACLWYQOMFIS-UHFFFAOYSA-N 0.000 claims 1
- GRUMYYBGXQJLOX-UHFFFAOYSA-N [5-[[5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]pyridin-2-yl]-[4-(4-fluorophenyl)piperazin-1-yl]methanone Chemical compound C1COCCC1N1C(C)=NC=C1C(C(=CN=1)F)=NC=1NC(C=N1)=CC=C1C(=O)N(CC1)CCN1C1=CC=C(F)C=C1 GRUMYYBGXQJLOX-UHFFFAOYSA-N 0.000 claims 1
- DTQCTPFWWBHEQQ-UHFFFAOYSA-N [5-[[5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]pyridin-2-yl]-[4-(4-fluorophenyl)piperidin-1-yl]methanone Chemical compound C1COCCC1N1C(C)=NC=C1C(C(=CN=1)F)=NC=1NC(C=N1)=CC=C1C(=O)N(CC1)CCC1C1=CC=C(F)C=C1 DTQCTPFWWBHEQQ-UHFFFAOYSA-N 0.000 claims 1
- MCSBEOQVHGWTJB-UHFFFAOYSA-N [5-[[5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]pyridin-2-yl]-piperidin-1-ylmethanone Chemical compound C1COCCC1N1C(C)=NC=C1C(C(=CN=1)F)=NC=1NC(C=N1)=CC=C1C(=O)N1CCCCC1 MCSBEOQVHGWTJB-UHFFFAOYSA-N 0.000 claims 1
- JUMYRNHMMUIHCS-UHFFFAOYSA-N [6-[[5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]pyridin-3-yl]-(4-methylpiperazin-1-yl)methanone Chemical compound C1CN(C)CCN1C(=O)C(C=N1)=CC=C1NC1=NC=C(F)C(C=2N(C(C)=NC=2)C2CCOCC2)=N1 JUMYRNHMMUIHCS-UHFFFAOYSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- DVWZSIRIFYGARA-UHFFFAOYSA-N azetidin-1-yl-[3-chloro-5-[[4-(2,3-dimethylimidazol-4-yl)-5-fluoropyrimidin-2-yl]amino]pyridin-2-yl]methanone Chemical compound CN1C(C)=NC=C1C1=NC(NC=2C=C(Cl)C(C(=O)N3CCC3)=NC=2)=NC=C1F DVWZSIRIFYGARA-UHFFFAOYSA-N 0.000 claims 1
- LORBIUKSEHFWJW-UHFFFAOYSA-N azetidin-1-yl-[3-chloro-5-[[5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]pyridin-2-yl]methanone Chemical compound C1COCCC1N1C(C)=NC=C1C(C(=CN=1)F)=NC=1NC(C=C1Cl)=CN=C1C(=O)N1CCC1 LORBIUKSEHFWJW-UHFFFAOYSA-N 0.000 claims 1
- IZZMQZVJRXUABE-UHFFFAOYSA-N azetidin-1-yl-[3-chloro-5-[[5-fluoro-4-[3-methyl-2-(trifluoromethyl)imidazol-4-yl]pyrimidin-2-yl]amino]pyridin-2-yl]methanone;hydrochloride Chemical compound Cl.N1=C(C(F)(F)F)N(C)C(C=2C(=CN=C(NC=3C=C(Cl)C(C(=O)N4CCC4)=NC=3)N=2)F)=C1 IZZMQZVJRXUABE-UHFFFAOYSA-N 0.000 claims 1
- YUDLMHLYKXMDDX-UHFFFAOYSA-N azetidin-1-yl-[5-[[4-(2,3-dimethylimidazol-4-yl)-5-fluoropyrimidin-2-yl]amino]pyridin-2-yl]methanone Chemical compound CN1C(C)=NC=C1C1=NC(NC=2C=NC(=CC=2)C(=O)N2CCC2)=NC=C1F YUDLMHLYKXMDDX-UHFFFAOYSA-N 0.000 claims 1
- LJANEJXMXPUPBQ-UHFFFAOYSA-N azetidin-1-yl-[5-[[5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]pyridin-2-yl]methanone Chemical compound C1COCCC1N1C(C)=NC=C1C(C(=CN=1)F)=NC=1NC(C=N1)=CC=C1C(=O)N1CCC1 LJANEJXMXPUPBQ-UHFFFAOYSA-N 0.000 claims 1
- 125000002393 azetidinyl group Chemical group 0.000 claims 1
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 claims 1
- 239000002585 base Substances 0.000 claims 1
- 150000003857 carboxamides Chemical class 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- SIZQTJGRHSEGQM-UHFFFAOYSA-N n,n-diethyl-5-[[5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]pyridine-2-carboxamide Chemical compound C1=NC(C(=O)N(CC)CC)=CC=C1NC1=NC=C(F)C(C=2N(C(C)=NC=2)C2CCOCC2)=N1 SIZQTJGRHSEGQM-UHFFFAOYSA-N 0.000 claims 1
- JBGTWXPZUUKCNY-UHFFFAOYSA-N n,n-dimethyl-5-[[4-[2-methyl-3-(oxan-4-yl)-2,4-dihydroimidazol-4-yl]pyrimidin-2-yl]amino]pyridine-2-sulfonamide Chemical compound CC1N=CC(C=2N=C(NC=3C=NC(=CC=3)S(=O)(=O)N(C)C)N=CC=2)N1C1CCOCC1 JBGTWXPZUUKCNY-UHFFFAOYSA-N 0.000 claims 1
- XQSRMCZTBCMDDX-UHFFFAOYSA-N n-(6-ethoxypyridin-3-yl)-5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-amine Chemical compound C1=NC(OCC)=CC=C1NC1=NC=C(F)C(C=2N(C(C)=NC=2)C2CCOCC2)=N1 XQSRMCZTBCMDDX-UHFFFAOYSA-N 0.000 claims 1
- CRWPLLBQGBOONW-UHFFFAOYSA-N n-(cyclopropylmethyl)-5-[[5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]-n-propylpyridine-2-carboxamide Chemical compound C=1C=C(NC=2N=C(C(F)=CN=2)C=2N(C(C)=NC=2)C2CCOCC2)C=NC=1C(=O)N(CCC)CC1CC1 CRWPLLBQGBOONW-UHFFFAOYSA-N 0.000 claims 1
- XGOXJRQESOESLO-UHFFFAOYSA-N n-benzyl-5-[[5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]-n-propan-2-ylpyridine-2-carboxamide Chemical compound C=1C=C(NC=2N=C(C(F)=CN=2)C=2N(C(C)=NC=2)C2CCOCC2)C=NC=1C(=O)N(C(C)C)CC1=CC=CC=C1 XGOXJRQESOESLO-UHFFFAOYSA-N 0.000 claims 1
- LRNMKMJMLOIJBL-UHFFFAOYSA-N n-benzyl-n-ethyl-5-[[5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]pyridine-2-carboxamide Chemical compound C=1C=C(NC=2N=C(C(F)=CN=2)C=2N(C(C)=NC=2)C2CCOCC2)C=NC=1C(=O)N(CC)CC1=CC=CC=C1 LRNMKMJMLOIJBL-UHFFFAOYSA-N 0.000 claims 1
- IMWKNRIKTUODBG-UHFFFAOYSA-N n-butan-2-yl-5-[[5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]-n-propylpyridine-2-carboxamide Chemical compound C1=NC(C(=O)N(C(C)CC)CCC)=CC=C1NC1=NC=C(F)C(C=2N(C(C)=NC=2)C2CCOCC2)=N1 IMWKNRIKTUODBG-UHFFFAOYSA-N 0.000 claims 1
- VBIAGKCTOMRLRW-UHFFFAOYSA-N n-ethyl-5-[[5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]-n-propan-2-ylpyridine-2-carboxamide Chemical compound C1=NC(C(=O)N(C(C)C)CC)=CC=C1NC1=NC=C(F)C(C=2N(C(C)=NC=2)C2CCOCC2)=N1 VBIAGKCTOMRLRW-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- YDVHAJGGRNBAER-UHFFFAOYSA-N pyrimidin-2-amine;hydrochloride Chemical compound Cl.NC1=NC=CC=N1 YDVHAJGGRNBAER-UHFFFAOYSA-N 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US81675606P | 2006-06-27 | 2006-06-27 | |
| PCT/SE2007/000620 WO2008002244A2 (en) | 2006-06-27 | 2007-06-26 | Imidazol-pyrimidine derivatives for treatment of diseases related to glycogen synthase kinase (gsk3) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009542638A JP2009542638A (ja) | 2009-12-03 |
| JP2009542638A5 true JP2009542638A5 (enExample) | 2010-08-12 |
Family
ID=38846127
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009518044A Pending JP2009542638A (ja) | 2006-06-27 | 2007-06-26 | グリコーゲン・シンターゼ・キナーゼ（ｇｓｋ３）に関連する疾患の治療のためのイミダゾール−ピリミジン誘導体 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20080188502A1 (enExample) |
| EP (1) | EP2046782A4 (enExample) |
| JP (1) | JP2009542638A (enExample) |
| KR (1) | KR20090024817A (enExample) |
| CN (1) | CN101511825A (enExample) |
| AR (1) | AR061652A1 (enExample) |
| AU (1) | AU2007265731A1 (enExample) |
| BR (1) | BRPI0713576A2 (enExample) |
| CA (1) | CA2655441A1 (enExample) |
| CL (1) | CL2007001881A1 (enExample) |
| CO (1) | CO6140059A2 (enExample) |
| EC (1) | ECSP088973A (enExample) |
| IL (1) | IL195666A0 (enExample) |
| MX (1) | MX2008015720A (enExample) |
| NO (1) | NO20090327L (enExample) |
| RU (1) | RU2008148902A (enExample) |
| TW (1) | TW200815418A (enExample) |
| UY (1) | UY30440A1 (enExample) |
| WO (1) | WO2008002244A2 (enExample) |
| ZA (1) | ZA200810484B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7745428B2 (en) | 2005-09-30 | 2010-06-29 | Astrazeneca Ab | Imidazo[1,2-A]pyridine having anti-cell-proliferation activity |
| AR058073A1 (es) * | 2005-10-03 | 2008-01-23 | Astrazeneca Ab | Derivados de imidazol 5-il-pirimidina, procesos de obtencion, composiciones farmaceuticas y usos |
| TW200811169A (en) * | 2006-05-26 | 2008-03-01 | Astrazeneca Ab | Chemical compounds |
| EP2431367A3 (en) | 2006-06-27 | 2012-07-04 | Takeda Pharmaceutical Company Limited | Fused cyclic compounds as GPR40 receptor modulators |
| TW200815417A (en) * | 2006-06-27 | 2008-04-01 | Astrazeneca Ab | New compounds II |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| CA2754685A1 (en) | 2009-03-11 | 2010-09-16 | Pfizer Inc. | Substituted indazole amides |
| RU2011140238A (ru) * | 2009-04-15 | 2013-05-20 | Астразенека Аб | Имидазол-замещенные пиримидины, полезные в лечении заболеваний, ассоциированных с киназой-3 гликогенсинтазы, таких как болезнь альцгеймера |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8933024B2 (en) | 2010-06-18 | 2015-01-13 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| CN103724207B (zh) * | 2013-12-20 | 2016-07-06 | 北京智博高科生物技术有限公司 | 苯基苄基醚类衍生物及其制备方法和应用 |
| WO2016008966A1 (en) | 2014-07-17 | 2016-01-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for treating neuromuscular junction-related diseases |
| UY36547A (es) | 2015-02-05 | 2016-06-01 | Bayer Cropscience Ag | Derivados heterocíclicos condensados bicíclicos sustituidos por 2-(het)arilo como pesticidas |
| WO2016207366A1 (en) | 2015-06-26 | 2016-12-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of viral infections |
| JP6913076B2 (ja) | 2015-08-07 | 2021-08-04 | バイエル・クロップサイエンス・アクチェンゲゼルシャフト | 有害生物防除剤としての２−（ヘタ）アリール−置換縮合ヘテロ環誘導体 |
| GB201519573D0 (en) | 2015-11-05 | 2015-12-23 | King S College London | Combination |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0021726D0 (en) * | 2000-09-05 | 2000-10-18 | Astrazeneca Ab | Chemical compounds |
| JP4570955B2 (ja) * | 2002-07-09 | 2010-10-27 | バーテクス ファーマスーティカルズ インコーポレイテッド | プロテインキナーゼ阻害活性を持つイミダゾール類 |
| JP2007500178A (ja) * | 2003-07-30 | 2007-01-11 | サイクラセル・リミテッド | プロテインキナーゼ阻害剤としてのピリジニルアミノ−ピリミジン誘導体 |
| JP5164380B2 (ja) * | 2003-10-21 | 2013-03-21 | サイクラセル リミテッド | ピリミジン−４−イル−３，４−チオン化合物及び治療におけるその使用 |
| GB0402653D0 (en) * | 2004-02-06 | 2004-03-10 | Cyclacel Ltd | Compounds |
| AU2005315392B2 (en) * | 2004-12-17 | 2010-03-11 | Astrazeneca Ab | 4- (4- (imidazol-4-yl) pyrimidin-2-ylamino) benzamides as CDK inhibitors |
| GB0504753D0 (en) * | 2005-03-08 | 2005-04-13 | Astrazeneca Ab | Chemical compounds |
| AR058073A1 (es) * | 2005-10-03 | 2008-01-23 | Astrazeneca Ab | Derivados de imidazol 5-il-pirimidina, procesos de obtencion, composiciones farmaceuticas y usos |
| TW200815417A (en) * | 2006-06-27 | 2008-04-01 | Astrazeneca Ab | New compounds II |
-
2007
- 2007-06-21 TW TW096122338A patent/TW200815418A/zh unknown
- 2007-06-26 RU RU2008148902/04A patent/RU2008148902A/ru not_active Application Discontinuation
- 2007-06-26 WO PCT/SE2007/000620 patent/WO2008002244A2/en not_active Ceased
- 2007-06-26 MX MX2008015720A patent/MX2008015720A/es not_active Application Discontinuation
- 2007-06-26 JP JP2009518044A patent/JP2009542638A/ja active Pending
- 2007-06-26 UY UY30440A patent/UY30440A1/es unknown
- 2007-06-26 AR ARP070102831A patent/AR061652A1/es not_active Application Discontinuation
- 2007-06-26 CN CNA2007800322107A patent/CN101511825A/zh active Pending
- 2007-06-26 CL CL200701881A patent/CL2007001881A1/es unknown
- 2007-06-26 AU AU2007265731A patent/AU2007265731A1/en not_active Abandoned
- 2007-06-26 BR BRPI0713576-9A patent/BRPI0713576A2/pt not_active IP Right Cessation
- 2007-06-26 CA CA002655441A patent/CA2655441A1/en not_active Abandoned
- 2007-06-26 KR KR1020097001642A patent/KR20090024817A/ko not_active Withdrawn
- 2007-06-26 EP EP07748281A patent/EP2046782A4/en not_active Withdrawn
- 2007-06-27 US US11/769,102 patent/US20080188502A1/en not_active Abandoned
-
2008
- 2008-12-02 IL IL195666A patent/IL195666A0/en unknown
- 2008-12-10 ZA ZA200810484A patent/ZA200810484B/xx unknown
- 2008-12-12 EC EC2008008973A patent/ECSP088973A/es unknown
- 2008-12-17 CO CO08134161A patent/CO6140059A2/es unknown
-
2009
- 2009-01-21 NO NO20090327A patent/NO20090327L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009542638A5 (enExample) | ||
| RU2008148902A (ru) | Производные имидазол-пиримидина для лечения заболеваний, связанных с киназой гликогенсинтазы 3 (gsk3) | |
| JP2009542639A5 (enExample) | ||
| JP2009513575A5 (enExample) | ||
| JP5311673B2 (ja) | Ｍｅｋ阻害剤の使用方法 | |
| CN107857755B (zh) | 作为trka激酶抑制剂的n-吡咯烷基、n′-吡唑基-脲、硫脲、胍和氰基胍化合物 | |
| JP2020111602A (ja) | 抗がんおよび抗増殖活性を示すｎ−アシル−ｎ’−（ピリジン−２−イル）尿素および類似体 | |
| RU2451674C2 (ru) | Пиридинкарбоксамиды в качестве ингибиторов 11-бета-hsd1 | |
| CN102292340B (zh) | 用作pde9 抑制剂的氨基-杂环类化合物 | |
| CN1960731B (zh) | 调节炎性和转移过程的方法 | |
| JP5650735B2 (ja) | タンパク質キナーゼ調節剤としてのピリジンおよびピラジン誘導体 | |
| RU2650895C2 (ru) | Соединения замещенных пиразолонов и способы использования | |
| JP5667684B2 (ja) | 関節炎の治療方法 | |
| CN115335043A (zh) | Pgdh抑制剂以及制备和使用方法 | |
| TW201927756A (zh) | 整合應激路徑之調節劑 | |
| US20160074409A1 (en) | Treatment of Skeletal-Related Disorders | |
| RU2008148903A (ru) | Производные имидазол-пиримидина для лечения заболеваний, ассоциированных с киназой гликогенсинтазы 3 (gsk3) | |
| RU2665036C2 (ru) | Гетероароматические соединения-модуляторы фосфоинозидит-3-киназы и способы применения | |
| JP2019530695A5 (enExample) | ||
| JP2010513288A5 (enExample) | ||
| JP2019505595A5 (enExample) | ||
| JP2009510161A5 (enExample) | ||
| CA2506308A1 (en) | Combination administration of an indolinone with a chemotherapeutic agent for cell proliferation disorders | |
| JP2021501145A5 (enExample) | ||
| JP2017513942A (ja) | Ｍｅｒｔｋ特異的ピロロピリミジン化合物 |